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A specific, precise, and accurate LC-UV method was developed and validated to assay raloxifene 
hydrochloride in rat plasma. Raloxifene was analyzed after liquid-liquid extraction and quantified by 
reversed phase liquid chromatography (C18 column) using acetonitrile and ammonium acetate buffer 
0.05 M (pH 4.0) as mobile phase at a flow rate of 1 mL.min-1 and UV detection at 287 nm. Retention 
times of raloxifene and internal standard (dexamethasone) were approximately 11 min and 14 min, 
respectively. Linearity was checked for a concentration range between 25 ng.mL-1 and 1000 ng.mL-1. 
Intra- and inter-day precision had relative standard deviation lower than 10% and 15%, respectively. 
Recovery from plasma was higher than 90%. Accuracy values were 98.21%, 99.70%, and 102.70% for 
lower, medium, and upper limits of quantification, respectively. Limit of quantification was 25 ng.mL-1. 
Drug stability was analyzed at room temperature using plasma kept in a freezer at -80 °C for 45 days 
after processing for 6 h and three freeze-thaw cycles. The advantages of the method developed include 
stability under different conditions and low limit of quantification. Its applicability was confirmed by 
the analysis of raloxifene levels in plasma samples in a designed pharmacokinetic study in rats after 
intravenous administration (5 mg.kg-1).
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INTRODUCTION
Characterized by reduced bone mass, osteoporosis 
affects women in the menopausal period. Raloxifene 
hydrochloride (RH; C28H27NO4S.HCl) is a selective 
estrogen receptor modulator with agonist effect on bones. 
It is usually administered to women for the prevention and 
treatment of osteoporosis (Morello, Wurz, DeGregorio, 
2003; Kayath, 1999). A 60-mg RH tablet is administered 
orally, when 60% of the dose is absorbed from the 
gastrointestinal tract and reaches absolute bioavailability 
of mere 2% (Morello, Wurz, DeGregorio, 2003). With 
an extensive intestinal and hepatic metabolism, RH has a 
half-life of 28 h (Kosaka et al., 2011; Jeong et al., 2005). 
The compound is extensively distributed in the body. 
Volume of distribution is not dose-dependent, and RH 
is highly bound to plasma proteins [98-99%] (Morello, 
Wurz, DeGregorio, 2003; Hochner-Celnikier, 1999). 
Most of the RH dose administered and the main part of its 
glucoronide metabolites are excreted in feces (Hochner-
Celnikier, 1999).
The quantification of RH in plasma has been 
described using different techniques, such as capillary 
electrophoresis (Pérez-Ruiz, 2004), liquid chromatography 
coupled to mass spectrometry (Trontelj et al., 2007), and 
ultra performance liquid chromatography (Jadhav, Ramaa, 
2012). Few articles have discussed the development and 
validation of an analytical method for the quantification 
of RH in rat plasma using liquid chromatography 
with ultraviolet detection (LC-UV). Nevertheless, the 
applicability of this technique has been investigated in the 
quantification of RH in drug dosage forms (Salazar et al., 
2015). Yang et al. (2007) validated a LC-UV method to 
determine raloxifene in rat plasma in a pharmacokinetic 
study, reporting a limit of quantification of 0.20 µg.mL-1 iD
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using 23 ºC as column temperature. On the other hand, 
Chen et al. (2010) conducted a RH pharmacokinetic study 
in rats based on a LC-UV method using a gradient elution 
of the mobile phase and a limit of quantification of 0.56 
µg.mL-1. However, to the best of our knowledge, simple 
and inexpensive pharmacokinetic analytical methods 
with low limits of quantification and excellent accuracy 
for the analysis of RH in biological samples have not 
been designed. In addition, Ravi, Aditya and Vats (2012) 
developed a LC-UV method to estimate RH levels in rabbit 
plasma with a limit of quantification of 0.05 µg.mL-1. It 
is important to highlight that these methods (Yang et al., 
2007; Chen et al., 2010; Ravi, Aditya, Vats, 2012) were 
based on a protein precipitation technique to extract the 
drug from rat or rabbit plasma.
In this scenario, the aims of this study were to 
develop and validate an analytical LC-UV method based 
on liquid-liquid technique to extract the drug from rat 
plasma. This approach was proposed to afford low limits 
of quantification to assay RH in rat plasma, considering the 
requirements for suitable application in a pharmacokinetic 
study after RH intravenous administration.
MATERIAL AND METHODS 
Material
Briefly, RH was obtained from Sequoia Research 
Products (Oxford, United Kingdom). Dexamethasone 
(internal standard - IS) was donated by Multilab Industry 
of Pharmaceutical Products Ltda (São Jerônimo, Brazil). 
Ammonium acetate was supplied by Stilolab Products for 
Laboratory (Porto Alegre, Brazil). Acetonitrile and methyl 
tert-butyl ether (MTBE) HPLC grade were purchased from 
Tedia (Rio de Janeiro, Brazil).
Apparatus and chromatographic conditions
An HPLC apparatus was used to carry out the 
validation study. The system consisted of a liquid 
chromatograph (10AD model, Shimadzu, Japan) with a 
SPD-M20AV detector, a degasser DGU-20A5, a CBM-
20A controller, a LC-20AT pump, and a SIL-20A auto 
sampler. Chromatographic separation was performed in 
a C18 column (150 mm x 4.6 mm, 5-µm particle size, 
110-Å pore diameter; Discovery®, Supelco Analytical, 
Sigma-Aldrich) and a mobile phase composed of 
acetonitrile 95% and 0.05 M ammonium acetate (28:72 
v/v) containing 0.2% glacial acetic acid at isocratic flow 
rate (1.0 mL.min-1). The mobile phase was filtered using a 
membrane (0.45 μm, Millipore®) and a vacuum pump, and 
degassed before use. The analysis was performed for 18 
min at 287 nm with injection volume of 40 µL. The ratio 
of peak area of RH to IS was used for the quantification 
of plasma samples.
Preparation of standard solutions
A RH stock solution was prepared dissolving 12.5 
mg of the drug in methanol in a volumetric flask (25 mL) 
to a final concentration of 0.5 mg.mL-1. This solution was 
stored in a freezer at -80 °C and was diluted with mobile 
phase to obtain a 50.0 µg.mL-1 solution, immediately 
before use. Working standard solutions were prepared 
daily by serial dilution of the solution at 50.0 µg.mL-1 
with the mobile phase to obtain analyte concentrations 
of 0.25, 0.50, 1.00, 2.50, 5.00, and 10.00 µg.mL-1. The 
internal standard (dexamethasone) working solution 
was prepared in methanol to yield a concentration of 
0.50 mg.mL-1 and diluted to 100.0 µg.mL-1 immediately 
before use.
The quality control plasma samples (QC) were 
prepared from a different stock solution from that used 
to generate the analytical curve samples using working 
standard solutions at 0.35, 4.50, and 9.00 µg.mL -1. 
These samples were used to evaluate intra- and inter-day 
variations.
Standard solutions in plasma
The samples of analytical curves (25.0, 50.0, 100.0, 
250.0, 500.0, and 1,000 ng.mL-1) were prepared using 90 
µL of blank rat plasma with 10 µL of internal standard 
and 10 µL of working standard solutions. The final 
concentration of internal standard was 10 µg.mL-1.
Sample preparation
Plasma samples were stored in a freezer at -80 °C 
upon analysis (for approximately 45 days). The liquid-
liquid technique was used to extract the drug from plasma. 
In an Eppendorf tube, 10 µL of internal standard was 
added to 100 µL of plasma samples, followed by vortex 
mixing for 5 s. The organic solvent MTBE (500 µL) 
was added for the extraction. Samples were shaken (10 
min) and centrifuged (6800 g for 10 min at 4 °C). The 
supernatants were transferred to tubes for evaporation of 
the organic solvent in a centrifuge at 40 °C. The pellets 
were resuspended with mobile phase (100 µL), stirred for 
5 s (vortex mixing), sonicated for 10 min, and assayed 
following the LC-UV method described above.
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Bioanalytical method validation
The method was validated according to the FDA 
Guidance – Bioanalytical Method Validation (2001) 
considering linearity, lower limit of quantification, 
specificity, precision, accuracy, and stability.
Linearity, lower limit of quantitation and specificity
To analyze linearity, six analytical curves prepared 
using six plasma concentrations in the range of 25.0 
ng.mL-1 to 1,000 ng.mL-1 (25.0, 50.0, 100.0, 250.0, 500.0, 
and 1,000 ng.mL-1) were assayed on two consecutive days. 
The drug was extracted from the biological samples and 
resuspended in 100 µL of the mobile phase according 
to the technique described in the “Sample preparation” 
section, followed by the LC-UV analysis. Each analytical 
curve was plotted using the average relative area of each 
concentration of the curve (peak area of RH/peak area of 
IS). The six concentrations of the standard solution were 
analyzed by linear regression to calculate the equation 
of the calibration curve and correlation coefficients. 
The lowest concentration of the analytical curve with 
acceptable precision and accuracy was considered the limit 
of quantification. Specificity of the method was analyzed 
assaying six blank plasma samples from rats. 
Precision and accuracy 
Intra- and inter-day precision as well as accuracy 
of the analytical method were determined calculating the 
standard deviation (SD) and relative standard deviation 
(RSD%) of three concentrations (low, medium, and high) 
in six replicate analysis. Samples were prepared with 80 
µL, 10 µL of the internal standard solution (10 µg.mL-1), 
and 10 µL of RH standard solution. The drug was extracted 
and resuspended in 100 µL of the mobile phase to reach 
concentrations of 35.0, 450.0, and 900 ng.mL-1 of RH as 
described above.
Recovery
Relative recovery was analyzed comparing the 
analytical results of extracted samples from three 
concentrations (35.0, 450.0, and 900 ng.mL-1) with those 
obtained from standard solution that is 100% of recovery. 
Stability
The stability of RH in rat plasma was performed 
using the low (35 ng.mL-1) and high (900 ng.mL-1) 
concentrations. The samples were analyzed in the short-
term (6 h on the workbench) after processing (6 h in 
autosampler), after three freeze-thaw cycles, and after 
long-term storage in freezer at -80 °C (45 days). 
Pharmacokinetic study
A pilot pharmacokinetic study was performed 
using male Wistar rats (n = 3), and the analytical method 
validated was evaluated to determine RH plasma 
concentration. The experiment was performed according 
to the Severity Guide of Scientific Procedures and as 
approved by Ethics Committee on Animal Use of the 
Federal University of Rio Grande do Sul (Protocol number 
22226). 
Three rats (250-350 g) were purchased from 
the Center for Reproduction and Experimentation of 
Laboratory Animal of Federal University of Rio Grande 
do Sul. The animals were exposed to daily 12-h dark-light 
cycles in a room with controlled temperature (22 ± 1 °C), 
relative humidity of approximately 65%, and were offered 
water and food ad libitum. 
On the day of the experiment, rats were anesthetized 
with urethane (1.25 g.kg-1) and the carotid artery was 
exposed for cannulation and subsequent blood collection 
(200 µL). A solution of RH (2.5 mg.mL-1) was prepared 
dissolving 12.5 mg of drug in 5 mL of glucose solution 
containing 5% of dimethylsulfoxide. This solution was 
administered as a 5-mg.kg-1 intravenous dose in the 
femoral vein. 
Blood samples were collected at time zero (before 
administration of drug) and 0.08, 0.17, 0.25, 0.5, 1.0, 
3.0, 6.0, 9.0, and 12.0 h after intravenous administration. 
Samples were centrifuged at 4 °C to separate the plasma 
(6800 g for 10 min) and stored in a freezer (-80 °C) upon 
analysis using the validated method described above. 
Plasma pharmacokinetic profiles of RH were analyzed by 
non-compartment approach using the Phoenix® Software 
(Certara, 2015, USA).
RESULTS AND DISCUSSION
Chromatograms of blank rat plasma and rat plasma 
containing RH (500 ng.mL-1) with internal standard (10 
µg.mL-1) are shown in Figure 1. The chromatograms 
confirm specificity of the method, since it was possible to 
separate RH and internal standard peaks from endogenous 
substances of plasma. The mean retention times of RH and 
internal standard were approximately 11 min and 14 min, 
respectively. Endogenous substances were detected until 
9 min into the run time of 18 min.
The mean analytical curve (25-1000 ng.mL-1) 
showed adequate linearity (r = 0.9986 ± 0.0012), angular 
coefficient (slope) of 0.0017 ± 0.0001, and an intercept 
of 0.0190 ± 0.0167. The limit of quantification was set 
at 25 ng.mL-1 of RH (which showed intra- and inter-
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day imprecision of 10.01% and 14.08%, respectively), 
accuracy of 96.19 ± 7.03%, and a recovery of 90.12 ± 
5.34%. These values are in agreement with the FDA 
guidelines (FDA Guidance – Bioanalytical Method 
Validation, 2001). Moreover, this limit of quantification 
value was lower than other limits of quantification 
previously reported in the literature for the RH assay 
in biological samples by LC-UV methods (Yang et al., 
2007; Chen et al., 2010; Ravi, Aditya, Vats, 2012), which 
can be explained considering the liquid-liquid extraction 
technique used in this study, compared with the methods 
of simple protein precipitation from rat (Yang et al., 2007; 
Chen et al., 2010) or rabbit (Ravi, Aditya, Vats, 2012) 
plasma used in previous studies.
Table I shows the results of precision (RSD), 
accuracy (%), and recovery (%) obtained in the analysis 
of samples containing RH 35 ng.mL-1, 450 ng.mL-1, 
and 900 ng.mL-1 (low, medium, and high concentration, 
respectively). 
The RSD results, comprising repeatability (intra-
day precision), and intermediate precision (inter-day 
precision) were lower than 10% and 15%, respectively. 
Accuracy was approximately 100%. Recovery, which 
represents extraction efficiency, was higher than 90% 
for the three concentrations, in accordance with previous 
reports (Yang et al., 2007). These results also agree with 
International Guidelines (FDA Guidance – Bioanalytical 
Method Validation, 2001).
The stability of the samples was studied according 
to the working conditions, using RH concentrations of 35 
ng.mL-1and 900 ng.mL-1. The results are shown in Table II. 
The maximum RSD of 8% demonstrates the stability 
of the analyte throughout sample processing. These 
results confirmed all requirements for a bioanalytical 
method according to international guidelines. Therefore, 
the method developed was tested again in a RH 
pharmacokinetic study in order to highlight its importance 
and contribution to pharmacokinetics.
FIGURE 1 - Chromatogram obtained for (A) blank plasma, (B) 
blank plasma with raloxifene hydrochloride at 500 ng.mL-1 
(RH), and internal standard 10 µg.mL-1 – (IS). 
TABLE I - Intra- and inter-day precision (RSD), accuracy (mean ± SD) and relative recovery (mean ± SD) for the RH quality 
controls in rat plasma (n = 6)
Concentration 
(ng.mL-1)
Intra-day precision 
(RSD, %)
Inter-day precision 
(RSD, %) Accuracy (%) Recovery (%)
35 9.68 14.84 98.21 ± 8.49 91.45 ± 4.62 
450 2.44 7.97 99.70 ± 7.89 94.21 ± 3.38
900 8.87 8.62 102.70 ± 8.76 92.10 ± 6.53
TABLE II - Stability of RH in rat plasma at two quality control levels (n = 3)
Condition Concentration (ng.mL-1) RH content ± SD (%) RSD (%)
Short-term 
35 100.52 ± 4.66 4.64
900 104.83 ± 8.39 8.00
Autosampler 
35 99.26 ± 4.00 4.03
900 100.08 ± 5.98 6.12
Freeze-thaw 
35 101.74 ± 5.90 6.09
900 97.05 ± 7.18 7.46
Long-term 
35 102.76 ± 4.78 4.99
900 97.89 ± 5.84 5.99
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Figure 2 shows the plasma pharmacokinetic 
profile after intravenous administration of RH 5 mg.kg-1 
(n = 3). A rapid distribution of the drug from plasma was 
observed. The pharmacokinetic parameters obtained after 
non-compartmental analysis were: AUC0-∞ = 1924.32 
± 264.42 ng.h.mL-1, λ = 0.20 ± 0.01 h-1, t1/2 = 3.45 ± 
0.23 h, MRT = 4.52 ± 0.17 h, CL = 2.94 ± 0.43 L.kg.h-1, 
Vdss = 13.26 ± 1.36 L.Kg-1. Furthermore, the analytical 
method showed sufficient sensitivity to detect very low 
RH plasma concentration, even at the last phase of the 
pharmacokinetic profile, when as little as 25 ng.mL-1 of 
drug was quantified. It would not be able to be detect 
such a low concentration of RH using LC-UV methods 
previously described in the literature to estimate the 
amounts of the drug in plasma.
The lack of methods with low limits of quantification 
of RH in rat plasma may be the reason why previous 
pharmacokinetic studies evaluated only relative 
bioavailability (Yang et al., 2007; Chen et al., 2010) due 
to the methodological restrictions to assay RH in the last 
phase. 
CONCLUSION
A method to assay RH in rat plasma for application 
to pharmacokinetic studies was developed and validated 
using LC-UV and a liquid-liquid technique to extract 
the drug from plasma. This method showed good 
accuracy, linearity, specificity, and precision, and was 
successfully used to analyze rat plasma samples in a pilot 
pharmacokinetic study. The validated method has notable 
advantages, like the lower limit of quantitation compared 
with other LC-UV methods previously described in 
the literature, a good resolution between the analyte 
and the plasma components, and RH stability under 
different conditions. The present analytical method is 
suitable for use in pharmacokinetic studies that require 
the quantification of very low concentrations of drug in 
plasma, such as studies involving the development of 
innovative formulations containing RH. 
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